EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Evaluation and optimization of sample size of neonates and infants for pediatric clinical studies on cefiderocol using a model‐based approach

Daichi Yamaguchi iD, Takayuki Katsube, Toshihiro Wajima

Pharmacology Research & Perspectives · 2024

DOI: 10.1002/prp2.70001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2024. Verfasst von Daichi Yamaguchi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology & Pharmacokinetics, Shionogi & Co., Ltd., Osaka, Japan. Hauptthemen laut MEDLINE: Cephalosporins, Anti-Bacterial Agents, Cefiderocol. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shionogi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

When planning pediatric clinical trials, optimizing the sample size of neonates/infants is essential because it is difficult to enroll these subjects. In this simulation study, we evaluated the sample size of neonates/infants using a model‐based optimal approach for identifying their pharmacokinetics for cefiderocol. We assessed the usefulness of data for estimation performance (accuracy and variance of parameter estimation) from adults and the impact of data from very young subjects, including preterm neonates. Stochastic simulation and estimation were utilized to assess the impact of sample size allocation for age categories in estimation performance for population pharmacokinetic parameters in pediatrics. The inclusion of adult pharmacokinetic information improved the estimation performance of population pharmacokinetic parameters as the coefficient of variation (CV) range of parameter estimation decreased from 4.9%–593.7% to 2.3%–17.3%. When sample size allocation was based on the age groups of gestational age and postnatal age, the data showed 15 neonates/infants would be necessary to appropriately estimate pediatric pharmacokinetic parameters (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CephalosporinsAnti-Bacterial AgentsCefiderocolHumansInfant, NewbornSample SizeInfantModels, BiologicalClinical Trials as TopicComputer SimulationAdultGestational AgeAge Factors

Stichwörter der Autor:innen

cefiderocolneonates and infantsoptimal designpopulation pharmacokineticsstochastic simulation and estimation

Substanzen

CephalosporinsAnti-Bacterial AgentsCefiderocol

Autor:innen und Institutionen

  • Clinical Pharmacology & Pharmacokinetics, Shionogi & Co., Ltd., Osaka, Japan.
  • Pharmacokinetics/Pharmacodynamics & Pharmacometrics, Japan Drug Development & Medical Affairs, Eli Lilly Japan K.K, Kobe, Japan.

ORCID-Profile: Daichi Yamaguchi

Förderung

  • Shionogi

Zitieren

APA

Yamaguchi, D., Katsube, T., & Wajima, T. (2024). Evaluation and optimization of sample size of neonates and infants for pediatric clinical studies on cefiderocol using a model‐based approach. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70001

Vancouver

Yamaguchi D, Katsube T, Wajima T. Evaluation and optimization of sample size of neonates and infants for pediatric clinical studies on cefiderocol using a model‐based approach. Pharmacology Research & Perspectives. 2024. doi:10.1002/prp2.70001

BibTeX
@article{Yamaguchi2024,
  author = {Yamaguchi, Daichi and Katsube, Takayuki and Wajima, Toshihiro},
  title = {Evaluation and optimization of sample size of neonates and infants for pediatric clinical studies on cefiderocol using a model‐based approach},
  journal = {Pharmacology Research & Perspectives},
  year = {2024},
  doi = {10.1002/prp2.70001}
}
Kostenlos starten →